Pharmafile Logo

News and Press Releases

Rockville-Based CRO Emmes Groups’ OptymEdge launch the first dedicated ophthalmology clinical trial platform at ARVO

Phase 1 will see new eSource technology launched at event, marking OptymEdge’s evolution into a full-service ophthalmic research partner 14 May 2025 -- Wisconsin, US -- OptymEdge – part of...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: May 14, 2025

OptymEdge
11414 West Park Place, Suite 202, Milwaukee, WI 53224, US

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes & Cartridges

Along with PCI’s own robust infrastructure expansions, acquisition furthers CDMO’s recent growth in sterile fill-finish, advanced drug delivery systems like prefilled syringes and cartridges, and biologics – including high potent assets for antibody-drug...

Category: Manufacturing and Packing, Pharmaceutical
Posted: May 1, 2025

PCI Pharma Services
talkfuture@pci.com
3001 Red Lion Road, Philadelphia, PA 19114, USA

FDA Grants OKYO Pharma Fast Track Designation to Urcosimod for Neuropathic Corneal Pain

1 May 2025 -- London, UK and New York, US -- OKYO Pharma Limited, an ophthalmology-focused bio-pharmaceutical company which is developing urcosimod (formerly called OK-101) to treat NCP, an ocular...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: May 1, 2025

OKYO Pharma
info@okyopharma.com
OKYO Pharma Floor 4, 14/15 Conduit St London W1S 2XJ

PCI Pharma Services to Acquire US-based Aseptic Fill-Finish CDMO Ajinomoto Althea

Acquisition creates a world-class large-scale manufacturing hub in San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high potent formulations such as ADCs, complementing existing global sterile...

Category: Logistics, Manufacturing and Packing, Pharmaceutical
Posted: April 24, 2025

PCI Pharma Services
talkfuture@pci.com
3001 Red Lion Road, Philadelphia, PA 19114, USA

Innovent Dosed First Participant in Phase 3 Clinical Study of IBI354 (Novel HER2 ADC) for Platinum-resistant Ovarian Cancer

24 March 2025 -- California, US and Suzhou, China -- Innovent Biologics, Inc, a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology,...

Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 24, 2025

Innovent
pr@innoventbio.com
1 Kingdom Street, Suite 445-446, London, W2 6BD, United Kingdom

PulseSight Therapeutics announces the initiation of the clinical plan of PST-611, Transferrin Vectorized Therapy for dry AMD/Geographic Atrophy

14 January 2025 -- Paris, France -- PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, today announces it has submitted a Clinical...

Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 14, 2025

PulseSight Therapeutics
contact@pulsesight.com
PariSanté Campus, 2-10 Rue d’Oradour-sur-Glane, 75015 Paris

Exonate appoints Dr Rafiq Hasan as Non-Executive Director

Appointment brings extensive experience in global pharma leadership and progressing ophthalmology drugs to market and further strengthens Board 28 May 2024 -- Cambridgeshire, UK -- Exonate, a biotechnology company developing...

Category: Biotechnology, Pharmaceutical
Posted: May 28, 2024

Exonate
info@exonate.com
WTL Moorfield Rd Duxford Cambridgeshire CB22 4PS United Kingdom